Akkermansia vs Butyrate
A side-by-side research comparison of Akkermansia and Butyrate across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Akkermansia | Butyrate |
|---|---|---|
| Full name | Akkermansia muciniphila (Pasteurized) | Sodium Butyrate / Tributyrin |
| Category | Gut Health | Gut Health |
| Status | Novel food / Supplement | Dietary supplement |
| Mechanism | Amuc_1100 outer membrane protein activates TLR2 signaling, strengthening gut barrier and improving metabolic endotoxemia. Stimulates mucin production by goblet cells. Enhances GLP-1 secretion and improves insulin signaling. | Inhibits histone deacetylases (HDACs) for anti-inflammatory gene expression. Fuels colonocyte mitochondria via beta-oxidation. Strengthens tight junctions by upregulating claudin-1 and ZO-1. Activates GPR109A to suppress NF-κB. |
| Molecular weight | Whole organism (not applicable) | 110.09 Da (sodium butyrate) |
| Half-life | Colonizes mucus layer; effects persist with continued use | ~30-40 minutes (rapidly metabolized by colonocytes) |
| Bioavailability | Oral - pasteurized form survives transit; live form colonizes | Tributyrin: ~60-80% delivery to colon; sodium butyrate: variable |
| Typical dose | 10 billion CFU (pasteurized) or 100mg membrane extract | 300-600 mg tributyrin or 500-2000 mg sodium butyrate |
| Frequency | Daily | 2-3x daily with meals |
| Route | Oral capsule | Oral (enteric-coated or tributyrin pro-drug) |
Akkermansia reported benefits
- Improved metabolic markers
- Reduced insulin resistance
- Gut barrier strengthening
- Weight management support
- Reduced systemic inflammation
- Enhanced GLP-1 secretion
Butyrate reported benefits
- Colonocyte energy support
- Tight junction integrity
- Reduced GI inflammation
- Healthy microbiome support
- Epigenetic modulation (HDAC inhibition)
- Improved insulin sensitivity
Related comparisons
Research and educational reference only. Not medical advice.